BioPharmaStock
HomeAsk About StockNewsIdeasHistoryFDA DesignationsElite Program

BDRX

No price yet

Announcements

Nothing here yet

Daily updates

  • Biodexa Recruits 100 Participants in Phase 3 Serenta Trial of eRapa for FAPOct 14, 2026

FDA designations

Nothing here yet

News

  • Biodexa announces another Serenta milestone, with 100 patients enrolled in its registrational Phase 3 trial for familial adenomatous polyposis (FAP)Oct 13, 2026
  • Biodexa announced a major milestone for its Serenta registrational Phase 3 trial in FAPAug 19, 2026
  • Biodexa launches support initiatives for FAP patients and treatment centers in FranceJul 29, 2026
  • Health Canada approved expansion of the Phase 3 Serenta registrational trial in FAPJun 29, 2026
  • Biodexa licensed Otsuka's OPB-171775 molecular glue for GIST from Phase 1 readyFeb 4, 2026

    Bio Pharma Stock

    Where Science Meets Investing.

    BioPharmaStock is a specialized biopharmaceutical investment intelligence company focused exclusively on publicly traded biotechnology and pharmaceutical companies. Our research team continuously analyzes clinical trials, FDA regulatory events, scientific publications, corporate developments, and market catalysts to deliver timely research and exclusive insights for investors seeking opportunities in one of the world's most knowledge-intensive sectors.

    ALNJAM ALAALI SOFTWARE DESIGN CO. L.L.C, UAE, Abu Dhabi

    BioPharmaStock LogoBioPharmaStock Logo

    Quick Links

    • Home
    • Ask About Stock
    • News
    • Ideas
    • History
    • FDA Designations
    • Elite Program

    Contact Us

    Email: info@biopharmastock.com

    Phone: +971 50 936 3328

    Join Our Community→

    Follow Us

    Get the App

    Instant notifications on your phone

    Download on theApp StoreGet it onGoogle Play

    © 2024-2026 Bio Pharma Stock. All rights reserved. Policy